Clinical implications of peripheral new bone formation in psoriatic arthritis : a literature-based review by A. Marchesoni et al.
310 Clinical and Experimental Rheumatology 2019
1Rheumatology Department, ASST 
Gaetano Pini-CTO, Milano, Italy; 
2Rheumatology Unit, Policlinico S. Matteo 
Foundation, University of Pavia, Italy; 
3Dipartimento di Medicina e Scienze della 
Salute “Vincenzo Tiberio”, Università 
degli Studi del Molise, Campobasso, Italy. 
Antonio Marchesoni, MD
Roberto Caporali, MD
Ennio Lubrano, MD, PhD
Please address correspondence to: 
Dr Antonio Marchesoni, 
Department of Rheumatology, 
Istituto Ortopedico Gaetano Pini, 
Piazza Cardinal Ferrari 1, 
20122 Milano, Italy. 
E-mail: 
antonio.marchesoni@asst-pini-cto.it
Received on January 23, 2018; accepted 
in revised form on May 29, 2018.
Clin Exp Rheumatol 2019; 37: 310-317.
© Copyright CliniCal and 
ExpErimEntal rhEumatology 2019.
Key words: psoriatic arthritis, 
bone damage, osteoproliferation, 
enthesophytes, imaging, DMARDs
Competing interests: E. Lubrano has 
received honoraria from BMS, Celgene 
and Novartis as speaker and member 
of Speakers’ bureau; the other authors 
have declared no competing interests.
ABSTRACT
While the destructive changes of peri-
pheral articular damage of psoriatic 
arthritis (PsA) are extensively studied, 
the productive modifications have been 
somewhat neglected. 
This literature-based study focuses on 
the clinically relevant aspects of pe-
ripheral bone proliferation in PsA. 
New bone proliferation frequently oc-
curs as juxta-articular and entheseal 
apposition in PsA patients but also in 
psoriatic patients without arthritis, the 
Psoriatic Arthritis Ratingen Score is 
the only radiographic method to evalu-
ate peri-articular new bone formation, 
numerous ultrasound systems to score 
entheseal changes have been proposed, 
several serum biomarkers of bone-turn-
over have been associated with PsA and 
psoriasis but they do not have clinical 
relevance. The effects of the biologics 
on peripheral new bone formation re-
mains to be elucidated as well as the 
contribution of peripheral bone apposi-
tion to disability.
Many aspects of peripheral osteo-
proliferation in PsA have not yet been 
properly addressed and represent clini-
cal unmet needs of this rheumatic dis-
order.
 Introduction
Whilst erosion is the typical feature of 
bone damage in rheumatoid arthritis 
(RA) and bone formation (syndesmo-
phytes and enthesophytes) is the dis-
tinctive trait of ankylosing spondylitis 
(AS), the structural damage of psoriatic 
arthritis (PsA) is characterised by the 
combination of both, providing a dis-
tinctive identity to this inflammatory 
disease (1-4). 
In addition to enthesophytes and syn-
desmophytes, patients with PsA may 
show periosteal thickening and bony 
ankylosing of the joints, suggesting a 
relevant role of new bone formation in 
PsA articular damage (5). In contrast 
to other inflammatory joint diseases, 
these typical expressions of new bone 
apposition might be caused by different 
pathogenetic mechanisms (6, 7). The 
relevance of bone apposition in PsA 
was also shown by the CASPAR study, 
where the juxta-articular new bone 
formation was the only radiographic 
feature predictive of PsA as opposed to 
other inflammatory rheumatic diseases; 
hence, it was included among the clas-
sification criteria (8).
Despite its relevance, articular damage 
progression due to new bone apposition 
has never been addressed by the ran-
domised controlled trials (RCTs) evalu-
ating the effects of new drugs in patients 
with PsA; therefore, during the 18° 
Target Therapies Meeting 2016, this is-
sue was recognised as a primary unmet 
need of PsA and placed in the transla-
tional science field alongside other key 
aspects related to disease pathogenesis 
and cytokines inter-relationship, and 
the development of predictive markers 
of disease onset and progression (9). 
A previous consensus forum on unmet 
needs in PsA had already highlighted 
the need for a more comprehensive as-
sessment of PsA progression (10).
Given the role of pathological new 
bone formation in PsA and the pauci-
ty of data on the clinical relevance of 
this feature, we carried out a literature 
search to address this topic.
Methods
The literature search was performed 
using two Internet engines (PubMed 
and EMBASE databases), selecting the 
items with the following criteria:
• Limits: humans, time window: 1980- 
February 2018.
• Inclusion criteria: phase-III RCTs, 
observational studies (prospective or 
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retrospective cohort studies, case-con-
trol studies, and case series studies), 
and English language publications.
• Exclusion criteria: studies in languag-
es other than English, case reports, 
letters, editorials, and grey literature.
An additional literature search was car-
ried out by hand searching in the refer-
ence lists of articles obtained by inter-
net engines, seeking among the articles 
published in the main Rheumatology 
journals, abstracts of 2014, 2015, 2016 
and 2017 EULAR and ACR meetings.
The key words were: psoriatic arthritis, 
bone damage, bone apposition, juxta-
articular bone formation, bone spur 
formation, bone remodelling, osteopro-
liferation, enthesophytes, bone forma-
tion biomarkers, imaging, radiography, 
DMARDs, biological drugs.
The process of literature screening and 
the output obtained for this review is 
showed in Figure 1.
Results
New bone formation in 
peripheral joints and entheses
Bony nodules in digit joints are the ex-
pression of new bone formation, typi-
cally found in areas different from those 
where erosions are usually seen. This 
observation suggests that osteoblast-
mediated unbalanced bone turnover is 
not necessarily linked to osteoclast-dis-
rupted homeostasis (5). This anatomi-
cal uncoupling between bone resorption 
and bone growth may also be detected 
in a single patient, possibly reflecting 
a different pattern of cytokines and 
growth factors in different musculo-
skeletal sites (11). The main occurrence 
of bone apposition was demonstrated at 
the entheses insertions, resulting in the 
formation of enthesophytes and syn-
desmophytes (12, 13). A comparative 
study of 30 RA and 58 PsA patients on 
the structural changes in the metacar-
pophalangeal (MCP) joints of the domi-
nant hand, evaluated by high-resolution 
micro-computerised tomography (CT), 
showed that PsA periarticular bone 
changes are different from RA lesions 
(13). Although PsA patients had the 
same number of bone erosions as RA 
patients, they were smaller in size and 
depth. Moreover, while RA erosions 
appeared U-shaped, PsA erosions were 
F- and tubule-shaped and more evenly 
distributed. In PsA patients osteophytes 
(as they were defined by the authors) 
were more numerous, more extended 
toward the radial and ulnar sites with a 
tendency to involve the whole circum-
ference of the periarticular bone surface 
(“bony corona”). A study evaluating the 
effect of adalimumab on the progres-
sion of bone damage in 41 PsA patients, 
found that at baseline, using standard 
radiography, 73% of patients had ero-
sions, 85% joint space narrowing, and 
68% new bone formation (14).
In digit joints, the inflammation of cap-
sular and local ligament attachments to 
the perichondral bone seems to be the 
main pathophysiologic mechanism un-
derlying enthesophyte formation and 
consequent bony nodules, with an os-
teoarthritis (OA)-like pattern (15). Al-
though a high-resolution quantitative 
CT study of the MCP joints showed 
that in PsA and OA bone spurs are pre-
sent in different sites (16), a synergistic 
overlap of these two articular disorders 
might occur in patients with both a pso-
riatic and an osteoarthritic trait (17).
The association between psoriasis 
(without PsA) and new bone formation 
around the MCP joints was proved by 
two micro-CT studies, suggesting that 
this psoriasis is a predisposing factor 
for bone apposition (18, 19). In these 
studies, periarticular enthesophytes 
were much more frequent in psoriatic 
patients than in healthy controls. More-
over, a higher prevalence of subclinical 
inflammatory lesions was found in pso-
riatic patients without PsA (20).
In PsA patients, new bone apposition 
may occur in any entheseal site. The 
CASPAR study assessed the sensitiv-
ity and specificity of plain radiograph 
features of peripheral enthesopathy at 
major sites in 588 PsA patients and 525 
patients with other inflammatory dis-
eases. New bone formation at sites of 
attachment of inguinal ligament, sarto-
rius and rectus femoris muscles to the 
ilium was significantly more frequent 
in PsA patients (OR 3.01, 95% CI 1.13-
8.02) than in patients with other inflam-
matory diseases (21). A recent study 
has shown that bony changes at hand 
flexor tendon insertions were signifi-
cantly more frequent in 37 PsA patients 
than in 47 RA patients and 10 healthy 
controls (22). All these findings are in 
line with the widely recognised notion 
that bony spurs secondary to enthesitis 
are the hallmark of the spondyloarthriti-
des (SpAs) and that they may be found 
at any entheseal insertion.  
In addition to iuxta-articular bone appo-
sition, psoriatic patients without arthri-
tis also have more peripheral entheso-
phytes than normal subjects, as showed 
by several ultrasound (US) studies (23, 
24, 25). 
The effects of PsA on bone minerali-
sation are still a matter of debate. In 
a study of 32 RA and 32 PsA patients 
(95% in cDMARD therapy, 12.5% 
RA and 34.5% PsA patients also tak-
ing tumour necrosis factor inhibitors 
(TNFis)), at 12 month follow-up, hand 
periarticular bone mineral density 
measured by digital x-ray radiogram-
metry showed a significant bone loss in 
RA patients but a significant bone gain 
in PsA patients (26). A study evaluat-
ing bone microstructure and volumet-
ric BMD by high-resolution peripheral 
quantitative CT of the distal radius in 
50 PsA patients showed that these pa-
tients had less bone changes than sero-
positive RA patients (27). However, us-
ing the same imaging technique, it was 
found that 50 PsA patients had a lesser 
degree of mineralisation than healthy 
controls and psoriatic patients without 
arthritis (28).
Imaging and scoring 
of new bone formation
In PsA, articular imaging is an essential 
tool for diagnosis, disease assessment, 
and treatment response. Since ultra-
sonography (US) and magnetic reso-
nance imaging (MRI) can detect overall 
musculoskeletal inflammation and bone 
changes, they have been widely consid-
ered the most reliable instruments for an 
early diagnosis. However, radiography 
is still the tool used to score joint dam-
age and to measure its progression (29), 
and it may help diagnosis and classifi-
cation. For instance, radiographic evi-
dence of a new bone formation may be 
the only sign pointing to PsA in patients 
with arthritis seronegative for the rheu-
matoid factor (30) and radiographic jux-
ta-articular bone formation is included 
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in the CASPAR criteria (8). The recent 
EULAR recommendations for the use 
of imaging in SpAs diagnosis and clini-
cal management, state that conventional 
radiography should be used to monitor 
structural damage of peripheral SpA 
and that MRI and US may provide ad-
ditional information (31). 
Scoring systems based on 
standard radiography
Most of the radiographic scoring sys-
tems aimed at evaluating bone damage 
in PsA are derived from existing scor-
ing methods for RA and AS. The fol-
lowing systems have been proposed 
to evaluate peripheral joint damage in 
PsA (Table I): the modified Steinbroker 
method, the modified Sharp score, the 
modified Sharp-van der Heijde score 
(SHS), and the Psoriatic Arthritis Rat-
ingen Score (PARS) (32, 33). 
In comparison with the original meth-
ods, these PsA versions were modified 
to account for typical features of this 
disease such as distal interphalangeal 
(DIP) joint involvement and osteolytic 
changes. The PARS is the only system 
specifically developed for PsA and, in 
contrast to the others, includes the eval-
uation of new bone formation (33). This 
method measures separately bone de-
struction and proliferation in 40 hands 
and feet joints. Each evaluated joint 
is scored from 0 to 5 for bone erosion 
and from 0 to 4 for bone proliferation 
(regardless of the type of bone apposi-
tion), for a total score ranging from 0 
to 360 (0-200 for erosion and 0-160 
for proliferation). These scoring sys-
tems proved to have a good feasibility, 
reliability, and sensitivity to change in 
PsA (34). The PARS had been validated 
by a previous study in 20 PsA patients 
whose radiographs were evaluated at a 
mean interval time of three years (33). 
This study showed a weak correlation 
between the destructive and prolifera-
tive changes suggesting the uncoupling 
between bone resorption and bone 
growth. A single-centre observational 
study in 72 patients with early PsA 
evaluated with the PARS at baseline 
and after five years revealed that the 
proliferation score contributed more 
than the destruction score to the change 
in the total score (35). 
Despite the importance of bone pro-
liferation in PsA peripheral joint dam-
age, the modified SHS, which measures 
only bone and cartilage destruction, has 
become the most used method to as-
sess the progression of joint damage in 
RCTs evaluating new drugs in PsA.
In a recently published proof-of-con-
cept study, a new simplified scoring 
method combining the SHS and PARS 
was applied on 22 joints (121 points) 
of hands and feet. This method encom-
passed all of the three typical features 
of PsA bone damage (erosions, joints 
space narrowing, and new bone forma-
tion) and showed sensitivity compara-
ble to the SHS (36). 
In contrast to the peripheral involve-
ment, the radiographic systems used to 
score PsA axial damage mainly evalu-
ate bone apposition (syndesmophytes). 
Both the modified Stoke Ankylosing 
Spondylitis Spine Score (mSASS) and 
the Bath Ankylosing Spondylitis Ra-
diographic Index (BASRI) have been 
validated for PsA spondylitis (37). A 
modified version of the BASRI (the 
PASRI), which includes the facet joints 
of three cervical vertebras, has been 
proposed to assess PsA spine damage 
(38). The reliability of these scoring 
methods in axial PsA has been con-
firmed by a study, which also showed 
that the PASRI might perform better 
than other systems (39). 
Scoring systems based on 
US, MRI and CT
In addition to the traditional radio-
graphic methods, the assessment of 
bone damage (including bone forma-
tion) in patients with PsA may benefit 
from newer imaging techniques such 
as, US, MRI, and micro-CT, which can 
detect the typical features of structural 
modifications in joints, periarticular 
tissues and spinal structures (40, 41, 
42). These imaging methods are more 
sensitive than standard radiography 
(43), but reliable and feasible scoring 
systems based on them are not exten-
sively used.
A PsA MRI scoring system (PsAMRIS) 
has been developed by the Outcome 
Measures in Rheumatology Clinical 
Trials (OMERACT) group to assess 
inflammatory and structural changes, 
including bone proliferation, in PsA 
hands (44, 45). An exercise conducted 
in a cohort of PsA patients treated with 
TNFis to test the performance of the 
PsAMRIS showed moderate/good re-
liability for most of the inflammatory 
features but a poor/untestable agree-
Fig. 1. Flow chart for the review studies selection.
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ment for bone proliferation (46). How-
ever, the results of this exercise were 
undermined by the very low values of 
structural damage. In a study evaluat-
ing adalimumab efficacy in reducing 
the evolution of bone damage in 41 
PsA patients, using CT as a standard 
reference, sensitivity and specificity for 
bone proliferation were 40% and 93% 
for the PsAMRIS, and 26% and 96% 
for the PARS (14).
In PsA, US imaging is widely em-
ployed to evaluate both joint and en-
theseal involvement, but scoring meth-
ods based on this technique have been 
developed only for enthesitis. Up until 
now numerous methods that evaluate 
simultaneously inflammatory activity 
and soft tissue damage and structural 
damage of bone have been proposed 
(47). These methods are heterogeneous 
in terms of entheseal sites to investigate 
and lesions grading, and an agreement 
on which to use has not been reached. 
A composite US score encompassing 
both joints and entheses and inflamma-
tory as well structural lesions has been 
proposed (48); however, given its com-
plexity, feasibility and reproducibility 
of this method need to be established.
CT should be the most sensitive and 
specific imaging method to score joint 
and entheseal bone changes, including 
osteo-proliferation, but scoring systems 
for peripheral PsA based on this tech-
nique are not available.
MRI is the current gold standard to de-
tect inflammatory changes in sacroiliac 
joints and spine of patients with axial 
SpA. A number of scoring methods 
based on MRI has been used to evalu-
ate the effect of various drugs on axial 
inflammation (31). Some of them also 
measure bone damage but MRI, as well 
as CT, is not a recommended instru-
ment to assess axial new bone forma-
tion in daily practice (31).
Biomarkers of new bone formation
Soluble biomarkers may be helpful for 
early diagnosis, assessment and moni-
toring of PsA activity, prognosis, and 
prediction of treatment response. As 
tissue remodelling is characteristic of 
PsA, most of the research in this field 
has focused on the products of bone, 
cartilage, and tendon turnover (49). 
The Group for Research and Assess-
ment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) identified biomarkers as one 
of its research priority (50), especially 
with regard to the prediction of struc-
tural damage (51). Nevertheless, the 
topic of biomarkers of articular tissue 
remodelling in PsA has been the subject 
of a limited number of investigations. A 
summary of the results of some of these 
studies is reported in Table II.
In a controlled study, 52 patients with 
psoriasis, 26 of whom with PsA accord-
ing to the CASPAR criteria, were com-
pared with 26 healthy controls (52). Se-
rum levels of receptor activator of nu-
clear factor-κB ligand (RANKL), TNF 
super family member 14 (TNFSF14), 
matrix metallo-proteinase (MMP)-3 
and cartilage oligometric matrix pro-
tein (COMP) were independently as-
sociated with psoriasis (p<0.05), while 
hsCRP, osteoprotegerin (OPG), MMP-
3 and C-propeptide of type II collagen 
(CPII):C2C ratio segregated PsA from 
psoriasis without arthritis (p<0.03) 
(52). Serum levels of OPG, leptin, dick-
kopf-1(Dkk-1), osteopontin (OPN), and 
sclerostin (SOST) were significantly 
higher in 60 patients with PsA than in 
patients with psoriasis without arthri-
tis (53). In a study enrolling patients 
with PsA (n=38), psoriasis (n=10), and 
healthy controls (n=12), patients were 
stratified according to peripheral joint 
bone changes on standard imaging. 
Macrophage-colony stimulating factor 
(M-CSF) and RANKL concentration 
were positively associated with radio-
graphic bone destructive changes but 
no correlation was found between the 
number of joints with new bone forma-
tion and serum concentration of me-
diators of bone remodelling and other 
factors (54). In this study, Dkk-1 serum 
levels were significantly higher in pso-
riatic patients but they did not correlate 
with bone changes (54). 
Serum levels of OPG, COMP, and IL-
20 were significantly higher in pso-
riatic patients than healthy controls, 
irrespective of the simultaneous pres-
ence of PsA (55). In a small study 11 
PsA patients had lower serum levels of 
osteocalcin (OCN) and higher levels of 
cathepsin K (CTSK), C-telopeptide of 
type I collagen (CTX-1), CTX-1/OCN 
and CTX-1/CTSK ratios than 8 patients 
with psoriasis and 14 healthy controls 
(51). In a longitudinal study, baseline 
serum levels of acute phase serum amy-
loid A (A-SAA) were independently as-
sociated with radiographic progression 
in RA (n=45) and PsA (n=17) patients. 
As A-SSA might stimulate the produc-
tion of MMPs and TNF-α by synovial 
tissue, its effects on joint damage might 
occur through these substances in both 
the diseases (56).
Table I. Main radiographic scoring systems used in PsA.
System Joint scored Features scored Score
Modified Steinbroker 42 of hands and feet, scale 0-4 Juxta-articular osteopenia, soft tissue swelling,    0-168
  erosion, JSN, joint destruction (lysis or ankylosis) 
Modified Sharp 42 hands, 12 feet, scale 0-5 JSN  JSN, discrete erosion, joint involvement by erosion,  0-486
 and for erosions extensive destruction 
Modified Sharp-van der Heijde (SHS) 42 hands, 10 feet, scale 0-5 for JSN  JSN, discrete erosion, large erosion 0-528
 and erosions not passing/passing midline, combination of above 
Psoriatic Arthritis Ratingen Score 30 hands, 10 feet scale 0-5 for destruction  Erosion, destruction 0-360
 30 hands, 10 feet scale 0-4 for proliferation Bony proliferation, bony ankylosis  0-160
  
JSN: joint space narrowing
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Bone proliferation and biologics
Notwithstanding biologic disease-
modifying anti-rheumatic drugs (bD-
MARDs) are considered the most effi-
cacious agents for the therapy of PsA, 
their possible effect on bone damage is 
only partially known (5) and their im-
pact on new bone formation has been 
scarcely studied. The phase III RCTs of 
all the TNFis available for the therapy 
of PsA showed that these drugs are 
capable of retarding radiographic pro-
gression as measured by the mSHS in 
the short and long term (57-66). How-
ever, as this scoring method includes 
only erosions and joint space narrow-
ing, these trials do not provide data on 
the effect of TNFis on the new bone 
formation.
Given the known capacity of TNF-α 
to promote osteoclastogenesis and in-
hibit bone formation mainly through the 
Dkk-1/Wnt mechanism (11, 67-69), not 
surprisingly the suppression of this cy-
tokine may reduce the destructive bone 
damage. However, data on the effects 
of TNFis on the serum levels of solu-
ble factors involved in bone turnover 
are scarce and unclear. TNFi influence 
on serum Dkk-1, RANKL and OPG was 
assessed in 27 PsA and 25 RA patients 
treated with these agents (70). After 
12-month treatment, the serum levels 
of Dkk-1 and RANKL had not changed 
while OPG levels were significantly 
higher only in RA patients. At this time 
point, Dkk-1 levels were lower in PsA 
than in RA patients but the difference 
was not significant. RANKL levels were 
higher at all time points in PsA patients 
(70).
In a small study of 41 patients with PsA, 
treatment with methotrexate (MTX) or 
TNF did not condition the pathologi-
cal new bone formation at the meta-
carpophalangeal joints, as measured by 
high-resolution micro-CT at 1 year (71). 
The size of the bony spurs significantly 
increased from baseline to one year re-
gardless of the therapy (mean ±SEM 
change +0.23±0.02 and +0.27±0.03 
in the TNFis and MTX group, respec-
tively) (71). In contrast, in an open-
label trial 41 PsA patients treated with 
adalimumab did not show a progression 
in erosive or proliferative hand bone 
changes after 48 weeks as measured by 
PARS, PsAMRIS, and CT (14).
Similarly to the TNFis, ustekinumab, 
and secukinumab (two new bDMARDs 
targeting the IL-23/IL-17 pathway) 
proved to be effective on the progres-
sion of joint bone destruction but their 
effect on new bone formation was not 
studied (72, 73).
Discussion
This review focused on aspects of new 
bone formation, mainly in the appendic-
ular skeleton, occurring in PsA patients 
that may have relevance in clinical prac-
tice. Exceeding bone can be found in the 
periarticular area of small joints and at 
the tendon insertions much more fre-
quently in PsA patients than in RA pa-
tients and healthy controls. These bony 
changes may also be seen in patients 
with psoriasis without clinical arthritis, 
suggesting that this feature is a general 
characteristic of the psoriatic disease. In 
the literature, PsA abnormal bone prolif-
erations in the peripheral skeleton have 
been referred to as enthesophytes, oste-
ophytes, or bony spurs. As this various 
terminology may be confusing (osteo-
phytes, for instance, are generally con-
sidered typical of OA), an agreement on 
the definitions should be reached. New 
bone formation in the peripheral skel-
eton is common in PsA, occurring at a 
periarticular level in about 70% of pa-
tients treated with TNFis and, at tendon 
insertion level, probably in nearly all the 
PsA patients. 
As the relationship between peripheral 
osteo-proliferation and patients’ dis-
ability has never been properly studied, 
the burden of this specific feature in 
PsA cannot be established. However, 
while enthesophytes at tendon inser-
tions per se are not likely to lead to 
function impairment, new bone appo-
sition in the joints may be responsible 
for various degrees of loss of articular 
movement up to joint ankyloses. It has 
been reported that, in the long term, 
new bone formation might contribute 
to total peripheral joint damage more 
than destructive changes (35).
Proliferative bony changes are clini-
cally relevant not only for their possi-
ble impact on joint function but also for 
their diagnostic usefulness. In fact, in 
patients with undifferentiated peripheral 
arthritis, the detection of periarticular 
bony spurs may be indicative of PsA. 
Similarly, in psoriatic patients with 
Table II. Main clinical studies regarding biomarkers of new bone formation in PsA.
Reference Type of study n./type of patients Intervention Results/Conclusions
Chandran, 2010 Cross-sectional 52 Serum levels of IL-12, IL-12p40, IL-17, Serum levels of hsCRP, OPG, and
  26 PsA and Pso; TNFSF14, MMP-3, RANKL, OPG, MMP-3, CPII:C2C ratio independently
  26 Pso; 26 HCs COMP, CPII, C1-2C, hsCRP. associated with PsA in patients with 
    psoriasis.
Abij, 2014 Cross-sectional analysis 120 Serum levels of Dkk-1, FGF23, IL-6; Serum levels of OPG, leptin, Dkk-1, 
  60 PsA; IL-1β, leptin, OCN, OPG, OPN, SOST OPN, and SOST higher in PsA patients. 
  60 Pso and TNF-α. 
Dalbeth, 2010 Cross-sectional 60 Serum levels of Dkk-1, M-CSF, OPG M-CSF and RANKL concentrations
  38 PsA;  and RANKL; patients stratified for associated with bone destruction; no
  10 Pso,  appendicular bone changes association found with bone
  12 HCs  proliferations
Connolly, 2012 Longitudinal 62 ESR and serum levels of A-SAA, CRP, A-SAA associate with bone damage
  45 RA; MMP-1), MMP-2, MMP-3, MMP-9, progression in RA and PsA 
  17 PsA MMP-13, TIMP-1), VEGF), C2C, C1,2C  
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widespread chronic pain, enthesophytes 
at the tendon insertions might help dis-
tinguish PsA from fibromyalgia (74).
Standard radiography is still widely 
used to detect bony lesions in PsA, even 
if US, MRI, and CT are more sensitive. 
The PARS is the only validated scoring 
system that includes the evaluation of 
periarticular proliferative changes but, 
in virtually all of the PsA RCTs, the 
SHS was the method used to measure 
the progression of joint damage. The 
US is more sensitive than traditional ra-
diography in revealing bony spurs and 
seems to be the best instrument to eval-
uate tendon insertions. While a number 
of scoring systems may be applied to 
measure entheseal involvement at the 
tendon insertions, no US-based method 
exists to quantify juxta-articular en-
thesophytes. MRI and CT are the most 
sensitive imaging methods to evalu-
ate peripheral bone apposition and the 
PsAMRIS, a MRI-based system that in-
cludes proliferative changes, has been 
proposed. However, because of limited 
availability, complexity or lack of scor-
ing methods and, for CT, high radiation 
dose, both MRI and CT will be likely 
restricted to research settings.
Serum biomarkers of bone turnover 
may represent an essential prognostic 
tool to early identify the most aggres-
sive subtypes of PsA (75) and they are 
being actively studied. Unfortunately, 
though several biomarkers associated 
with peripheral osteo-proliferation have 
been discovered, robust confirming 
studies have not been performed. The 
development of multiplex assays of bi-
omarkers, based on mass spectrometry 
able to quantitatively measure proteins, 
may provide a validation of the identi-
fied biomarkers (76). Whether serum 
biomarkers predicting peripheral bone 
apposition in PsA will ever be helpful 
in clinical practice remains unknown.
The inflammatory cytokines targeted 
by the bDMARDs currently available 
for the PsA therapy (TNF-α, IL-12/23, 
IL-17) are likely to play a relevant role 
in the pathophysiology of peripheral os-
teo-proliferation (77), but how their in-
hibition might alter this process has not 
been elucidated. Theoretically, TNF-α 
blocking might enhance new bone for-
mation by the effect of this cytokine on 
the Dkk-1/Wnt interaction; however, 
as this mechanism might be counter-
balanced by the anti-inflammatory ef-
fect of TNF-α inhibition, the final re-
sult of this inhibition remains obscure. 
Surprisingly enough, all of the pivotal 
RCTs that studied the effects of the bD-
MARDs in PsA have focused only on 
bone and cartilage destruction. TNFis, 
IL-12/23 inhibitors, and IL-17 inhibi-
tor all proved their efficacy in reducing 
progression of joint erosions and space 
narrowing but their effect on new bone 
formation was not studied. The few ex-
isting studies on this issue do not pro-
vide enough data for evidence-based 
conclusions. The lack of information 
about the effects of the bDMARDs on 
peripheral bone proliferation can be 
considered an important unmet need in 
the field of the therapy of PsA.
In conclusion, periarticular and en-
theseal osteoproliferation has relevant 
clinical implications in PsA. Transla-
tional researches fully addressing this 
topic are needed.
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